Beneficial effects of statins after percutaneous coronary intervention

Abstract

Background

Evidence about the efficacy of statin treatment among patients after percutaneous coronary intervention

(PCI) is very limited. The rapid advancement in PCI technology and near universal use of adjunctive cardioprotective medications make it necessary to formally assess the effect of statin therapy on cardiac events after PCI.

Design

This was a multicenter prospective cohort study.

Methods

Patients who received stent implantation and survived to hospital discharge from the National Heart, Lung, and Blood Institute Dynamic Registry from 2004 to 2006 formed the study cohort. Patients with cardiogenic shock, in-hospital adverse events [including myocardial infarction and coronary artery bypass graft surgery (CABG)], liver disease, renal disease, alcoholism, or drug abuse were excluded. The occurrences of death, CABG, and repeat PCI, and repeat revascularization were collected over 1-year follow-up.

Results

Of the 3227 patients evaluated, 2737 (85%) were prescribed a statin at discharge. By 1-year follow-up, incident events were 98 deaths, 44 CABG, 290 repeat PCI procedures, and 328 repeat revascularizations. After propensity score adjustment, postdischarge statin therapy was associated with lower risks of death [hazard ratio (HR): 0.58, 95% confidence interval (CI): 0.36–0.93, P = 0.02], CABG (HR: 0.49, 95% CI: 0.24–1.00, P = 0.05), and repeat revascularization (HR: 0.74, 95% CI: 0.56–1.00, P = 0.05).

Conclusion

These results support the routine use of statin therapy after PCI.

Keywords

mortality propensity score repeat revascularization stent

Get full access to this article

View all access options for this article.

References

1 The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383–1389.

2 The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339:1349–1357.

3 Strandberg

Pyorala

Cook

Wilhelmsen

Faergeman

Thorgeirsson

. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004; 364:771–777.

4 Hong

Jeong

Hyun

Hur

Kim

. Prognostic significance of simvastatin therapy in patients with ischemic heart failure who underwent percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2005; 95:619–622.

5 Chan

Bhatt

Chew

Quinn

Moliterno

Topol

. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002; 105:691–696.

6 Yamawaki

Yamada

Fukumoto

Kishi

Sobashima

Kuwata

. Statin therapy may prevent restenosis after successful coronary intervention, independent of lipid-lowering effect and CRP level. Fukuoka Igaku Zasshi 2007; 98:260–269.

Mood

Bavry

Roukoz

Bhatt

DL.

Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention. Am J Cardiol 2007; 100:919–923.

Rosenbaum

Rubin

DB.

The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41–55.

Rosenbaum

Rubin

DB.

Reducing bias in observational studies. J Am Stat Assoc 1984; 79:516–524.

10.

Robins

Hernan

Brumback

Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11:550–560.

11.

11 Kasai

Miyauchi

Kurata

Satoh

Ohta

Tanimoto

. Long-term (11-year) statin therapy following percutaneous coronary intervention improves clinical outcome and is not associated with increased malignancy. Int J Cardiol 2007; 114:210–217.

12.

12 Serruys

Foley

Jackson

Bonnier

Macaya

Vrolix

. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the Fluvastatin Angiographic Restenosis (FLARE) trial. Eur Heart J 1999; 20:58–69.

13.

13 Weintraub

Boccuzzi

Klein

Kosinski

King

3rd Ivanhoe

. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. N Engl J Med 1994; 331:1331–1337.

14.

14 Bertrand

McFadden

Fruchart

Van Belle

Commeau

Grollier

. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of restenosis by elisor after transluminal coronary angioplasty. J Am Coll Cardiol 1997; 30:863–869.

15.

15 Serruys

de Feyter

Macaya

Kokott

Puel

Vrolix

. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 287:3215–3222.

16.

Tailor

Lefer

Granger

DN.

HMG-CoA reductase inhibitor attenuates platelet adhesion in intestinal venules of hypercholesterolemic mice. Am J Physiol Heart Circu Physiol 2004; 286:H1402–H1407.

17.

Lacoste

Lam

Hung

Letchacovski

Solymoss

Waters

Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92:3172–3177.

18.

18 Guven

Atalar

Yavuz

Beyazit

Kekilli

Kilicarslan

. Simvastatin treatment improves endothelial function and increases fibrinolysis in patients with hypercholestrolemia. J Natl Med Assoc 2006; 98:627–630.

19.

Crisby

Nordin-Fredriksson

Shah

Yano

Zhu

Nilsson

Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103:926–933.

20.

20 Sattar

Murray

McConnachie

Blauw

Bollen

ELEM

Buckley

. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 2007; 115:981–989.

21.

21 Nissen

Nicholls

Sipahi

Libby

Raichlen

Ballantyne

. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295:1556–1565.

22.

22 Baetta

Donetti

Comparato

Calore

Rossi

Teruzzi

. Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells. Pharmacol Res 1997; 36:115–121.

23.

23 Guijarro

Blanco-Colio

Ortego

Alonso

Ortiz

Plaza

. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998; 83:490–500.

24.

Corsini

Pazzucconi

Pfister

Paoletti

Sirtori

CR.

Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin. Lancet 1996; 348:1584.

25.

25 Buemi

Allegra

Senatore

Marino

Medici

Aloisi

. Pro-apoptotic effect of fluvastatin on human smooth muscle cells. Eur J Pharmacol 1999; 370:201–203.

26.

Sahni

Maniet

Voci

Banka

VS.

Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J 1991; 121 (6 Pt 1):1600–1608.

27.

27 Schartl

Bocksch

Koschyk

Voelker

Karsch

Kreuzer

. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 2001; 104:387–392.